Cancer Chemotherapy and Pharmacology

, Volume 65, Issue 6, pp 1153–1163 | Cite as

Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse

  • Iris-Susanne Horn
  • Gunnar Wichmann
  • Christian Mozet
  • Andreas Dietz
  • Ralph Dollner
  • Katrin Tschöp
  • Andreas Boehm
Original Article

Abstract

Background

Valid prediction of the effectiveness of chemotherapeutic agents in individual head and neck squamous cell carcinoma (HNSCC) is desirable and might be achieved using ex vivo assays.

Methods

Three biopsies from each of 15 HNSCC were taken, minced and digested by collagenase. The digested HNSCC was added to serial dilutions of either cisplatin (CIS) or docetaxel (DTX), which were prepared under flavin-protecting conditions in ECM-coated microtiterplates. After 72-h incubation, cultures were methanol-fixed and Giemsa-stained. The cutoff concentration (COC; concentration completely suppressing colony formation) for epithelial cells (EC) and stromal cells (SC) was evaluated.

Results

12/15 HNSCC (80%) were evaluable. Despite significant correlation of COC of CIS in respect of colony formation of EC or SC, no significant differences in response of individual HNSCC specimens were found in the t test for paired samples (p > 0.16). The same applied to DTX. However, EC and SC showed heterogeneity in chemoresponses leading to COC variability of more than one titration step in 44.1% (CIS) and 20% of HNSCC (DTX). No significant correlation between the COC of both cell populations was found in HNSCC specimens.

Conclusions

The ex vivo chemoresponse of EC and SC of HNSCC must be analyzed separately.

Keywords

Heterogeneity HNSCC Ex vivo chemoresponse Epithelial cells Stromal cells 

Notes

Acknowledgments

The authors wish to thank Anett Reiche and Grit Müller for their excellent technical assistance.

References

  1. 1.
    Wright JL, Cobb JP, Gumport SL, Golomb FM, Safadi D (1957) Investigation of the relation between clinical and tissue culture response to chemotherapeutic agents of human cancer. N Engl J Med 257:1207–1211PubMedCrossRefGoogle Scholar
  2. 2.
    DiPaolo JA, Dowd JE (1961) Evaluation of inhibition of human tumor tissue by cancer chemotherapeutic drugs with an in vitro test. J Natl Cancer Inst 27:807–815PubMedGoogle Scholar
  3. 3.
    Courtenay VD, Mills J (1978) An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents. Br J Cancer 37:261–268PubMedGoogle Scholar
  4. 4.
    Freeman AE, Hoffman RM (1986) In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83:2694–2698CrossRefPubMedGoogle Scholar
  5. 5.
    Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffmann RM (1987) In vivo-like drug responses of human tumors growing in three-dimensional, gel-supported, primary culture. Proc Natl Acad Sci USA 84:5029–5033CrossRefPubMedGoogle Scholar
  6. 6.
    Vescio RA, Connors KM, Bordin GM, Robb JA, Youngkin T, Umbreit JN, Hoffmann RM (1990) The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture. Cancer Res 50:6095–6099PubMedGoogle Scholar
  7. 7.
    Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Kase S, Kodaira S, Ishibiki K, Kitajima M (1992) High in vitro correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 51:489–498CrossRefPubMedGoogle Scholar
  8. 8.
    Robbins KT, Varki NM, Storniolo AM, Hoffman H, Hoffman RM (1991) Drug response of head and neck tumors in native-state histoculture. Arch Otolaryngol Head Neck Surg 117:83–86PubMedGoogle Scholar
  9. 9.
    Von Hoff DD (1990) He’s not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 82:96–101CrossRefGoogle Scholar
  10. 10.
    Dollner R, Granzow C, Werner JA, Dietz A (2004) Is there a role for chemosensitivity tests in head and neck cancer? Onkologie 27:310–315CrossRefPubMedGoogle Scholar
  11. 11.
    Weisenthal LM, Lippman ME (1985) Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 69:615–632PubMedGoogle Scholar
  12. 12.
    Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schröder U, Eckel H, Hess M, Schröder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M (2009) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol 266(8):1291–1300CrossRefPubMedGoogle Scholar
  13. 13.
    Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR (2006) Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int 6:25. doi:10.1186/1475-2867-6-25 CrossRefPubMedGoogle Scholar
  14. 14.
    Rajamaran R, Rajaraman MM, Rajaraman SR, Guernsey DL (2005) Neosis: a paradigm of self-renewal in cancer. Cell Biol Int 29:1084–1097CrossRefGoogle Scholar
  15. 15.
    Heuser M, Kopun M, Rittgen W, Granzow C (2005) Cytotoxicity determination without photochemical artifacts. Cancer Lett 223:57–66CrossRefPubMedGoogle Scholar
  16. 16.
    Granzow C, Kopun M, Kröber T (1995) Riboflavin-mediated photosensitization of Vinca alkaloids distorts drug sensitivity assays. Cancer Res 55:4837–4843PubMedGoogle Scholar
  17. 17.
    Wichmann G, Horn I-S, Boehm A, Mozet C, Tschöp K, Dollner R, Dietz A (2009) Single biopsies from head and neck squamous cell carcinomas are representative regarding the entire tumor’s chemosensitivity to cisplatin and docetaxel. Onkologie 32(5):264–272CrossRefPubMedGoogle Scholar
  18. 18.
    Dietz A, Tschöp K, Wichmann G, Granzow C (2008) Method and kit for the ex vivo evaluation of the response of a tumor to conditions to be tested. US-Provisional Ser. No. 61/044,082Google Scholar
  19. 19.
    Cabelguenne A, Blons H, Waziers De I, Carnot F, Houllier A-M, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P (2000) p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18:1465–1473PubMedGoogle Scholar
  20. 20.
    Fouret P, Temam S, Charlotte F, Lacau-St-Guily J (2002) Tumor stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumor response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br J Cancer 87:1390–1395CrossRefPubMedGoogle Scholar
  21. 21.
    Hoffmann TK, Sonkoly E, Hauser U, Lierop A, Whiteside TL, Klussmann JP, Hafner D, Schuler P, Friebe-Hoffmann U, Scheckenbach K, Erjala K, Gréman R, Schipper J, Bier H, Balz V (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44(12):1100–1109CrossRefPubMedGoogle Scholar
  22. 22.
    Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR (2004) Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 26:870–877CrossRefPubMedGoogle Scholar
  23. 23.
    American Joint Committee on Cancer: Comparison Guide: Cancer Staging Manual Fifth versus Sixth Edition. http://www.cancerstaging.org/products/ajccguide.pdf. Accessed 31 March 2009
  24. 24.
    Dollner R, Kopun M, Dietz A, Wiessler M, Granzow C (2002) Chemoreactivity profiling of HNSCC: equipotentiality of platinum compounds and glufosfamide, a novel alkylating agent. Proc Am Assn Cancer Res 43:926–931Google Scholar
  25. 25.
    Dollner R, Granzow C, Helmke BM, Ruess A, Schad A, Dietz A (2004) The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 24:325–331PubMedGoogle Scholar
  26. 26.
    Desoize B, Berthiot G, Manot L, Coninx P, Dumont P (1996) Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Eur J Cancer A 32:1734–1738CrossRefGoogle Scholar
  27. 27.
    Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ (1993) Phase I and pharmakokinetic study of Taxotere (RP 56976) administered as a 24-h infusion. Cancer Res 53:523–527PubMedGoogle Scholar
  28. 28.
    Witz IP, Levy-Nissenbaum O (2006) The tumor microenvironment in the post-PAGET era. Cancer Lett 242:1–10CrossRefPubMedGoogle Scholar
  29. 29.
    Freeman AE, Hoffman RM (1986) In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83:2694–2698CrossRefPubMedGoogle Scholar
  30. 30.
    Dollner R, Granzow C, Neudert M, Dietz A (2006) Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res 26:1651–1655PubMedGoogle Scholar
  31. 31.
    Granzow C, Kopun M, Heuser M, Herth F, Becker HD (2004) Chemoresistance of human lung tumor stromal cells. Am Assn Cancer Res 95th Annual Meeting Proc Suppl. abstract LB-82Google Scholar
  32. 32.
    Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T (2007) Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43:749–756CrossRefPubMedGoogle Scholar
  33. 33.
    Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24:437–442CrossRefPubMedGoogle Scholar
  34. 34.
    Mukaida H, Hirabayashi N, Hirai T, Iwata T, Saeki S, Toge T (1991) Significance of freshly cultured fibroblasts from different tissues in promoting cancer cell growth. Int J Cancer 48:423–427CrossRefPubMedGoogle Scholar
  35. 35.
    Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL (2006) Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 6:52CrossRefPubMedGoogle Scholar
  36. 36.
    Rosenthal EL, McCrory A, Talbert M, Carroll W, Magnuson JS, Peters GE (2004) Expression of proteolytic enzymes in head and neck cancer-associated fibroblasts. Arch Otolaryng Head Nack Surg 130:943–947CrossRefGoogle Scholar
  37. 37.
    Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ, Roy-Burman P (2000) The effect of fibroblast growth factor 8, isoform b, on the biology of prostata carcinoma cells and their interaction with stromal cells. Cancer Res 60:6730–6736PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Iris-Susanne Horn
    • 1
  • Gunnar Wichmann
    • 1
  • Christian Mozet
    • 1
  • Andreas Dietz
    • 1
  • Ralph Dollner
    • 2
  • Katrin Tschöp
    • 1
  • Andreas Boehm
    • 1
  1. 1.Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Hospital LeipzigLeipzigGermany
  2. 2.Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Hospital OsloOsloNorway

Personalised recommendations